cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Charles River Laboratories International
6 own
6 watching
Current Price
$250.35
$-9.57
(-3.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
12,737.06M
52-Week High
52-Week High
349.84
52-Week Low
52-Week Low
181.36
Average Volume
Average Volume
0.41M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
48.7805
iconMarket Capitalization12,737.06M
icon52-Week High349.84
icon52-Week Low181.36
iconAverage Volume0.41M
iconDividend Yield--
iconP/E Ratio48.7805
What does the Charles River Laboratories International do?
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening preclinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More
How much money does Charles River Laboratories International make?
News & Events about Charles River Laboratories International.
Business Wire
6days ago
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired SAMDI Tech, Inc, a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition marks the culmination of a partnership between the...
Globe Newswire
10days ago
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: ...
Business Wire
18days ago
Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics...
Business Wire
20days ago
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrimeTM suite of Good Manufacturing Practice (GMP)-compliant cellular starting materials. CliniPrime products provide rapid access to starting materials for cell, and gene-modified cell therapies...
Benzinga
24days ago
Over the past three months, shares of Charles River Inc. (NYSE:CRL) increased by 16.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials. read more...
Frequently Asked Questions
Frequently Asked Questions
What is Charles River Laboratories International share price today?
plus_minus_icon
Can Indians buy Charles River Laboratories International shares?
plus_minus_icon
How can I buy Charles River Laboratories International shares from India?
plus_minus_icon
Can Fractional shares of Charles River Laboratories International be purchased?
plus_minus_icon
What are the documents required to start investing in Charles River Laboratories International stocks?
plus_minus_icon
What is today’s traded volume of Charles River Laboratories International?
plus_minus_icon
What is today’s market capitalisation of Charles River Laboratories International?
plus_minus_icon
What is the 52-Week High and Low Range of Charles River Laboratories International?
plus_minus_icon
What percentage is Charles River Laboratories International down from its 52-Week High?
plus_minus_icon
What percentage is Charles River Laboratories International up from its 52-Week Low?
plus_minus_icon
Current Price
$250.35
$-9.57
(-3.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$470.88
$-9.61 (-2.00 %)
United Therapeutics Corporation
United Therapeutics Corporation
$252.80
$-6.68 (-2.57 %)
Teleflex Incorporated
Teleflex Incorporated
$258.47
$-3.75 (-1.43 %)
Bio-Techne Corp.
Bio-Techne Corp.
$79.16
$-1.69 (-2.09 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$470.88
$-9.61 (-2.00 %)
United Therapeutics Corporation
United Therapeutics Corporation
$252.80
$-6.68 (-2.57 %)
Teleflex Incorporated
Teleflex Incorporated
$258.47
$-3.75 (-1.43 %)
Bio-Techne Corp.
Bio-Techne Corp.
$79.16
$-1.69 (-2.09 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00